Title: I-125 seeds brachytherapy with transcatheter arterial chemoembolization for subcapsular
hepatocellular carcinoma
Version: 0 Date: 06 Apr 2022
Reviewer's report:
To the authors:
“I-125 seeds brachytherapy with transcatheter arterial chemoembolization for subcapsular
hepatocellular carcinoma”
My comments are as follows.
1. How did you calculate Age and Diameter in Table 1? If you used the mean for them, you
should describe the standard deviation, if you used the median for them, you should describe
the range.
2. Please show the rationale for setting the cut-off value of AFP to 400 ng/mL.
3. There is no indication for TACE in patients with BCLC stage A. Please analyze focus on
BCLC stage B-C.
I hope that my comments will be useful in improving the article.
Title: I-125 seeds brachytherapy with transcatheter arterial chemoembolization for subcapsular
hepatocellular carcinoma
Version: 0 Date: 06 Apr 2022
Reviewer's report:
To the authors:
“I-125 seeds brachytherapy with transcatheter arterial chemoembolization for subcapsular
hepatocellular carcinoma”
My comments are as follows.
1. How did you calculate Age and Diameter in Table 1? If you used the mean for them, you
should describe the standard deviation, if you used the median for them, you should describe
the range.
2. Please show the rationale for setting the cut-off value of AFP to 400 ng/mL.
3. There is no indication for TACE in patients with BCLC stage A. Please analyze focus on
BCLC stage B-C.
I hope that my comments will be useful in improving the article.
Please review this paper.
user
Title: I-125 seeds brachytherapy with transcatheter arterial chemoembolization for subcapsular
hepatocellular carcinoma
Version: 0 Date: 06 Apr 2022
Reviewer's report:
To the authors:
“I-125 seeds brachytherapy with transcatheter arterial chemoembolization for subcapsular
hepatocellular carcinoma”
My comments are as follows.
1. How did you calculate Age and Diameter in Table 1? If you used the mean for them, you
should describe the standard deviation, if you used the median for them, you should describe
the range.
2. Please show the rationale for setting the cut-off value of AFP to 400 ng/mL.
3. There is no indication for TACE in patients with BCLC stage A. Please analyze focus on
BCLC stage B-C.
I hope that my comments will be useful in improving the article.
assistant